CRISPR is one of this generation’s most profound innovations, with the potential to fundamentally alter the realm of modern ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.82% at $54.00. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of ...

The company had fallen out of investor favor; its recovery was impressive.

The limits of Anthropic’s finding also point to a more fundamental issue. What made Crispr revolutionary was that scientists ...

Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood ...

Anthropic announced today that its Claude artificial intelligence (AI) system identified a previously unknown biological ...

A patient in Germany has been successfully treated with a drug based on CRISPR gene-editing technology for the first time since the therapy was approved, the Charité medical school and hospital in ...

Anthropic’s AI-driven discovery of a new CRISPR-like enzyme system has pressured gene-editing stocks, but the technology ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

Anthropic's AI agent Claude discovered ART, a new CRISPR-like enzyme system, after scanning 200,000 candidates in one day at ...

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...